New hope for kids with aggressive cancer: Two-Year treatment aims to keep disease at bay
NCT ID NCT07278674
Summary
This study is testing whether a drug called eflornithine, taken for two years, can help children with high-risk neuroblastoma stay cancer-free after they finish their main treatments, including immunotherapy. Researchers will follow 20 children under 18 to see if this maintenance therapy improves survival and prevents the cancer from coming back. The study will also closely monitor the safety and side effects of taking eflornithine for this extended period.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIGH RISK NEUROBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ruijin Hospital Hainan Branch, affiliated with Shanghai Jiao Tong University School of Medicine and Children's Hospital of Shanghai, affiliated with Shanghai Jiao Tong University School of Medicine
Hainan, China
Conditions
Explore the condition pages connected to this study.